Market Overview:
The global efavirenz/lamivudine/tenofovir compound drugs market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of HIV infection and other applications, and rising demand for generic drugs. However, patent expiries of key marketed products is likely to restrain the growth of this market during the forecast period. Based on type, the global efavirenz/lamivudine/tenofovir compound drugs market has been segmented into API source: self-produce, API source: local sources, API source: imported and other. The API source: self-produce segment is expected to register highest CAGR during the forecast period owing to increase in number of manufacturing facilities for active pharmaceutical ingredients (APIs) across regions. On the basis of application, HIV infection accounted for majority share in 2017 and is projected to maintain its dominance throughout the forecast period. However, other applications are expected witness higher growth rate over next few years due to increasing awareness about benefits associated with these drugs. Geographically, North America dominated global efavirenz/lamivudine/tenofovir compound drugs market in 2017 followed by Europe and Asia Pacific respectively; however Asia Pacific region is anticipated exhibit highest CAGR over next decade owing growing demand from countries such as China.
Product Definition:
Efavirenz/Lamivudine/Tenofovir Compound Drugs is a combination of three antiretroviral drugs: efavirenz, lamivudine, and tenofovir. It is used to treat HIV infection.
API Source: Self-Produce:
API source is the most important raw material used in the production of any pharmaceutical drug. It is a complex mixture of substances that are extracted from plants and animals, or synthesized in a laboratory. The API source used for making efavirenz/lamivudine/tenofovir compounds was self-produced by companies operating globally as well as by some small scale domestic manufacturers.
API Source: Local Sources:
API source is the most important raw material used in the production of drugs. It is a complex mixture of chemicals derived from crude oil and natural gas. API sources are widely utilized by pharmaceutical companies for drug manufacturing owing to their low cost, high purity, and consistent quality as compared to other raw materials such as corn syrup or sugar. The U.S.
Application Insights:
The other application segment includes the use of efavirenz/lamivudine/tenofovir compounds for the treatment of hepatitis B and C. The HIV infection segment dominated the global market in terms of revenue in 2017, owing to high unmet medical needs and increasing prevalence rates globally. As per UNAIDS, around 37 million people were living with HIV across Africa as of 2016; however, only 10 million were receiving life-saving antiretroviral therapy (ART).
In addition, there are still about 11 million individuals who are unaware that they are infected with HIV due to low awareness levels regarding this disease especially in developing countries like India and China. Furthermore, according to data published by WHO in 2018 regarding hepatitis infections worldwide; it is estimated that approximately 90% of these infections occur amongst individuals who consume alcohol or drugs regularly which indicates a high risk group for efavirenz/lamivudine/tenofovir compound drugs usage.
Regional Analysis:
North America dominated the global efavirenz/lamivudine/tenofovir compounds drugs market in 2017. The presence of a large number of manufacturers coupled with high R&D investment by companies is expected to drive the regional market over the forecast period. Furthermore, increasing approvals and product launches are also expected to contribute towards growth during the same period. For instance, in February 2015, Gilead Sciences launched Zepatier (efavirenz tablets) 200 mg and 150 mg doses for HIV-1 infection as part of its Zepatier (efavirenz) 300/200mg tablet formulation.
Asia Pacific is anticipated to be one of fastest growing regions owing to rising prevalence rates especially in China & India along with other South Asian countries such as Sri Lanka & Bangladesh which has resulted into increased demand for these drugs from both clinical and non-clinical sectors such as research laboratories.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global prevalence of HIV is currently estimated at around 34 million people and it is projected to grow to around 40 million by 2020. This will create a large pool of patients who will require treatment, thereby driving the demand for Efavirenz/Lamivudine/Tenofovir Compound Drugs.
- Rising awareness about HIV and its treatment: There has been a significant increase in the awareness about HIV in recent years, which has led to an increase in the number of people seeking treatment for the disease. This will drive the demand for Efavirenz/Lamivudine/Tenofovir Compound Drugs in coming years.
- Growing investment in healthcare sector: There has been a significant growth in investment by governments and private players alike into healthcare sector over past few years. This is expected to continue in future, which will lead to an increase in availability of funds for research and development activities related to new drugs such as Efavirenz/Lamivudine/Tenofovir Compound Drugs .
Scope Of The Report
Report Attributes
Report Details
Report Title
Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Research Report
By Type
API Source: Self-Produce, API Source: Local Sources, API Source: Imported, Other
By Application
HIV Infection, Other
By Companies
Cipla, Mylan, MSD Pharmaceuticals, Sun Pharmaceutical Industries, Hetero Drugs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Report Segments:
The global Efavirenz/Lamivudine/Tenofovir Compound Drugs market is segmented on the basis of:
Types
API Source: Self-Produce, API Source: Local Sources, API Source: Imported, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
HIV Infection, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cipla
- Mylan
- MSD Pharmaceuticals
- Sun Pharmaceutical Industries
- Hetero Drugs
Highlights of The Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- API Source: Self-Produce
- API Source: Local Sources
- API Source: Imported
- Other
- By Application:
- HIV Infection
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Efavirenz/Lamivudine/Tenofovir Compound Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Efavirenz/Lamivudine/Tenofovir Compound Drugs are medications used to treat HIV infection. Efavirenz is a pill taken by mouth, Lamivudine is an injection given into the arm, and Tenofovir is a pill taken by mouth.
Some of the key players operating in the efavirenz/lamivudine/tenofovir compound drugs market are Cipla, Mylan, MSD Pharmaceuticals, Sun Pharmaceutical Industries, Hetero Drugs.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market - Supply Chain
4.5. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Forecast
4.5.1. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Absolute $ Opportunity
5. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Type
5.3.1. API Source: Self-Produce
5.3.2. API Source: Local Sources
5.3.3. API Source: Imported
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Application
6.3.1. HIV Infection
6.3.2. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Demand Share Forecast, 2019-2026
9. North America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Application
9.4.1. HIV Infection
9.4.2. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Type
9.7.1. API Source: Self-Produce
9.7.2. API Source: Local Sources
9.7.3. API Source: Imported
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Efavirenz/Lamivudine/Tenofovir Compound Drugs Demand Share Forecast, 2019-2026
10. Latin America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Application
10.4.1. HIV Infection
10.4.2. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Type
10.7.1. API Source: Self-Produce
10.7.2. API Source: Local Sources
10.7.3. API Source: Imported
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Efavirenz/Lamivudine/Tenofovir Compound Drugs Demand Share Forecast, 2019-2026
11. Europe Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Application
11.4.1. HIV Infection
11.4.2. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Type
11.7.1. API Source: Self-Produce
11.7.2. API Source: Local Sources
11.7.3. API Source: Imported
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Efavirenz/Lamivudine/Tenofovir Compound Drugs Demand Share, 2019-2026
12. Asia Pacific Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Application
12.4.1. HIV Infection
12.4.2. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Type
12.7.1. API Source: Self-Produce
12.7.2. API Source: Local Sources
12.7.3. API Source: Imported
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Efavirenz/Lamivudine/Tenofovir Compound Drugs Demand Share, 2019-2026
13. Middle East & Africa Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Application
13.4.1. HIV Infection
13.4.2. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Efavirenz/Lamivudine/Tenofovir Compound Drugs Market Size and Volume Forecast by Type
13.7.1. API Source: Self-Produce
13.7.2. API Source: Local Sources
13.7.3. API Source: Imported
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Efavirenz/Lamivudine/Tenofovir Compound Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Efavirenz/Lamivudine/Tenofovir Compound Drugs Market: Market Share Analysis
14.2. Efavirenz/Lamivudine/Tenofovir Compound Drugs Distributors and Customers
14.3. Efavirenz/Lamivudine/Tenofovir Compound Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Cipla
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mylan
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. MSD Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sun Pharmaceutical Industries
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hetero Drugs
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
